UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-768-9780
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.13 million
Profitability
Miscellaneous
Employees70
Next Earnings Date11/11/2019 (Estimated)
OptionableOptionable
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) released its quarterly earnings data on Friday, August, 9th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.12. The business earned $0.02 million during the quarter. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
8 brokerages have issued 1-year price objectives for Urogen Pharma's shares. Their predictions range from $41.00 to $77.00. On average, they anticipate Urogen Pharma's stock price to reach $61.57 in the next year. This suggests a possible upside of 190.0% from the stock's current price. View Analyst Price Targets for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating after URGN’s investor day as we came away more bullish on UGN-101 as a treatment for LG-UTUC based on commentary from the physician panel which we believe did a good job addressing many of the investor concerns we hear. Additionally, URGN also reported encouraging results for UGN-102 in LG-NMIBC. While we concede LG-UTUC is a small market, we think investors are meaningfully discounting UGN-101’s commercial potential in the face of the clear unmet need for a non-surgical, kidney sparing treatment which was highlighted by the panel. UGN-101 has a high probability of approval, in our view, though we think shares could be range bound until approval/ launch, likely in 1H20." (9/24/2019)
- 2. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (7/30/2019)
Has Urogen Pharma been receiving favorable news coverage?
Headlines about URGN stock have trended negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Urogen Pharma earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Urogen Pharma.
Are investors shorting Urogen Pharma?
Urogen Pharma saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 2,440,000 shares, an increase of 7.5% from the August 30th total of 2,270,000 shares. Based on an average daily volume of 243,200 shares, the short-interest ratio is presently 10.0 days. Currently, 14.3% of the shares of the stock are short sold. View Urogen Pharma's Current Options Chain.
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Deciphera Pharmaceuticals (DCPH), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Pacira Biosciences (PCRX), Tricida (TCDA), Aimmune Therapeutics (AIMT), Insmed (INSM), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN) and Nabriva Therapeutics (NBRV).
What other stocks do shareholders of Urogen Pharma own?
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
- Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
- Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $21.23.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $443.71 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.View Additional Information About Urogen Pharma.
What is Urogen Pharma's official website?
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
